What you can expect
-
A talk from Stefan Duhr, NanoTemper CEO
A forward-looking talk on where biophysical characterization is headed, including emerging market trends and cutting-edge research directions.
-
Rotating lab stations
Explore affinity and stability applications at dedicated instrument stations.
-
Panel discussion
An open conversation with leading voices in the NanoTemper Team.
-
Monolith Omni showcase
A show-and-tell featuring NanoTemper's newly launched Monolith Omni, a platform for in-solution binding kinetics that requires no immobilization and minimal sample consumption.
-
User talks & case studies
Hear directly from researchers using NanoTemper's technologies in their work.
-
Lunch & networking
Dedicated time to connect with fellow users and the NanoTemper team over lunch, posters, and vendor tables.
-
10:00 AM – 10:15 AM
Arrival: Check-in, coffee, snacks, and casual networking
-
10:15 AM – 10:30 AM
Welcome address: Opening remarks and technology overview from CEO Stefan Duhr
-
10:30 AM – 10:50 AM
Guest speaker 1 - tbd
-
10:50 AM – 11:10 AM
Guest speaker 2 - tbd
-
11:10 AM – 11:20 AM
Break
-
11:20 AM – 12:00 PM
Breakout application stations - tbd
-
12:00 PM – 01:30 PM
Complimentary lunch, with posters and vendor tables
-
01:30 PM – 01:50 PM
Guest speaker 3 - tbd
-
01:50 PM – 02:10 PM
Guest Speaker 4 - tbd
-
02:10 PM – 02:20 PM
Short break
-
02:20 PM – 02:40 PM
Talk by Stefan Duhr, NanoTemper CEO: "The Future of NanoTemper" — A forward-looking session on where biophysical characterization is headed
-
02:40 PM – 03:00 PM
Talk by Nathan Wallace, PhD: “Introduction to Monolith Omni” — Overview on the technology behind Monolith Omni: binding, kinetics, and stability in one workflow
-
03:00 PM – 03:20 PM
Omni Show & Tell — Sample experiment and data analysis
-
03:20 PM – 03:50 PM
Panel discussion — NanoTemper Team and guest speakers
-
03:50 PM – 04:00 PM
Closing remarks and raffle
Speaker information
Derrick Meinhold
Director of Biophysics, WuXi AppTec
With 14 years in drug discovery across large pharma and biotech, Derrick has helped guide 19 programs to clinical candidates, from an HIV capsid inhibitor to a WRN inhibitor for MSI-high cancer. He's known for designing sharp, fit-for-purpose experiments that cut through ambiguity and help teams make better decisions, faster.